0.00Open3.60Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-53.68%PremiumAug 16, 2024Expiry Date4.09Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.25Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Karyopharm Therapeutics Stock Discussion
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...
No comment yet